In this trial, 60% of patients had provoked clots, similar to real world prevalence of DVTs(compared to 5% in amplify-ext). Guidelines do not recommend any extended therapy for these patients.
1. Do you think the provoked patients included we're perceived as risky provoked patients by their referring providers?
2. How do you think this affects the results and the comparison to apixaban?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.